Dr. Reddy's Lab launches Neostigmine Methylsulfate Injection in US

14 Sep 2018 Evaluate

Dr. Reddy's Laboratories has launched Neostigmine Methylsulfate Injection, USP, a therapeutic equivalent generic version of Bloxiverz (Neostigmine Methylsulfate) Injection in the US market, approved by the US Food and Drug Administration (USFDA).

The Bloxiverz brand and generic had US sales of approximately $111 million MAT for the most recent twelve months ending in July 2018 according to IMS Health. Dr. Reddy's Neostigmine Methylsulfate Injection, USP is available in 5 mg/10 ml and 10 mg/10 ml multi-dose vials.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1303.90 -9.15 (-0.70%)
06-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1798.95
Dr. Reddys Lab 1303.90
Cipla 1321.75
Zydus Lifesciences 912.95
Lupin 2344.45
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×